

January 6, 2020



## Anixa Biosciences Announces Presentation at AACR Liquid Biopsies Conference

SAN JOSE, Calif., Jan. 6, 2020 /PRNewswire/ -- [Anixa Biosciences, Inc.](#) (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system in the fight against cancer, today announced that data from studies utilizing Cchek™, the company's artificial intelligence (AI) driven cancer detection technology, will be presented at the American Association for Cancer Research (AACR) Special Conference on Advances in Liquid Biopsies. The presentation will review data related to Anixa's recently launched Cchek™ Prostate Cancer Confirmation test.

The AACR conference takes place January 13 – January 16, 2020 at the Hilton Miami Downtown in Miami, Florida and is designed to showcase the latest advances in liquid biopsies and how they may be translated into the clinic. The meeting will be attended by U.S. and international basic scientists, translational researchers, and clinicians.

Details of the poster presentation are as follows:

**Abstract title:** Using pattern recognition neural networks to detect prostate cancer: a new method to analyze flow cytometry-based immunophenotyping using machine learning

**Author:** George Dominguez

**Session:** Poster Session B

**Session Date and Start Time:** Wednesday, January 15, 2020 at 12:30 p.m. ET

### About Cchek™

Cchek™ is an early cancer detection technology, that measures a patient's immunological response to a malignancy by analyzing immune system cells in peripheral blood. The goal is to utilize the technology to determine a patient's cancer status from a simple blood draw, eliminating the need for a biopsy, which can be an expensive, painful and invasive procedure. Further, conventional methods using current cancer screening tests often lack accuracy and reliability. Anixa's orthogonal approach using flow cytometry coupled with artificial intelligence provides an alternative method that offers improved affordability, efficacy and efficiency. To date, Anixa has successfully used Cchek™ to detect the presence of 20 different cancers including lung, colon, breast and prostate. The robust cancer detection

performance of Cchek™ makes it a platform from which multiple cancer diagnostic tests may be developed. On December 16, 2019, Anixa announced the commercial launch of the Cchek™ Prostate Cancer Confirmation test (Cchek™ PCC), the first test developed with the Cchek™ liquid biopsy technology.

**About Anixa Biosciences, Inc.**

Anixa is a publicly-traded biotechnology company focused on harnessing the body's immune system in the fight against cancer. Anixa's therapeutic portfolio includes a cancer vaccine technology focused on the immunization against  $\alpha$ -Lactalbumin to prevent triple negative breast cancer (TNBC), as well as a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology. The company's diagnostic portfolio consists of Cchek™, a liquid biopsy technology for early detection of solid tumors based on the body's immune response to the presence of a malignancy. Anixa continually examines emerging technologies in complementary fields for further development and commercialization. Additional information is available at [www.anixa.com](http://www.anixa.com).

**Forward-Looking Statements:** Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements.

These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.

Anixa contact:  
Mike Catelani  
[mcatelani@anixa.com](mailto:mcatelani@anixa.com)  
408-708-9808

[Tiberend Strategic Advisors, Inc.](#)

Miriam Miller (Investors)  
[mmiller@tiberend.com](mailto:mmiller@tiberend.com)  
212-375-2694

Johanna Bennett (Media)  
[jbennett@tiberend.com](mailto:jbennett@tiberend.com)  
212-375-2686

 View original content to download multimedia <http://www.prnewswire.com/news-releases/anixa-biosciences-announces-presentation-at-aacr-liquid-biopsies-conference-300981179.html>

SOURCE Anixa Biosciences, Inc.